
Company valuation, historical trends, and peer comparisons.
According to Arcellx, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.75B. This represents a change of 73.09% compared to the average of 3.90B of the last 4 quarters.
The mean historical Enterprise Value of Arcellx, Inc. over the last ten years is 1.61B. The current 6.75B Enterprise Value has changed 318.68% with respect to the historical average. Over the past ten years (40 quarters), ACLX's Enterprise Value was at its highest in in the September 2025 quarter at 4.62B. The Enterprise Value was at its lowest in in the December 2020 quarter at 0.
Average
1.61B
Median
970.05M
Minimum
-11748239.20
Maximum
4.06B
Discovering the peaks and valleys of Arcellx, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 160.95%
Maximum Annual Enterprise Value = 4.06B
Minimum Annual Increase = -4779.37%
Minimum Annual Enterprise Value = -11748239.20
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 3.69B | -9.10% |
| 2024 | 4.06B | 71.12% |
| 2023 | 2.37B | 70.49% |
| 2022 | 1.39B | 160.95% |
| 2021 | 532.80M | 66.89% |
| 2020 | 319.25M | -41.93% |
| 2019 | 549.74M | -4779.37% |
The current Enterprise Value of Arcellx, Inc. (ACLX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.37B
5-year avg
2.41B
10-year avg
1.61B
Arcellx, Inc.’s Enterprise Value is less than Alkermes plc (8.58B), greater than NewAmsterdam Pharma Company N.V. (1.91B), greater than Akero Therapeutics, Inc. (4.32B), less than Protagonist Therapeutics, Inc. (8.75B), less than Arrowhead Pharmaceuticals, Inc. (9.26B), less than Kymera Therapeutics, Inc. (10.40B), greater than Viking Therapeutics, Inc. (2.99B), greater than Immunovant, Inc. (5.18B), greater than CRISPR Therapeutics AG (5.36B), less than Vaxcyte, Inc. (9.42B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 8.58B | $7.52B | |
| 1.91B | $2.34B | |
| 4.32B | $4.50B | |
| 8.75B | $9.16B | |
| 9.26B | $8.45B | |
| 10.40B | $10.70B | |
| 2.99B | $3.41B | |
| 5.18B | $5.98B | |
| 5.36B | $4.87B | |
| 9.42B | $9.49B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcellx, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcellx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Arcellx, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Arcellx, Inc. (ACLX)?
What is the 3-year average Enterprise Value for Arcellx, Inc. (ACLX)?
What is the 5-year average Enterprise Value for Arcellx, Inc. (ACLX)?
How does the current Enterprise Value for Arcellx, Inc. (ACLX) compare to its historical average?